Allakos Inc. (ALLK)
Stock Price:
$68.71 USD
-0.16 (-0.23%)
Updated Jul 9, 2020 12:16 PM EDT - Market open
Key Info
| Market Cap |
3.35B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-93.24M |
| Shares Out |
48.77M |
| EPS (ttm) |
-2.00 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 9, 2020 |
| Last Price |
$68.71 |
| Previous Close |
$68.86 |
| Change ($) |
-0.16 |
| Change (%) |
-0.23% |
| Day's Open |
69.05 |
| Day's Range |
67.60 - 70.97 |
| Day's Volume |
44,367 |
| 52-Week Range |
30.32 - 139.99 |
More Stats
| Market Cap |
3.35B |
| Enterprise Value |
2.87B |
| Earnings Date (est) |
Aug 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
48.77M |
| Float |
24.59M |
| EPS (basic) |
-1.99 |
| EPS (diluted) |
-2.00 |
| FCF / Share |
-1.42 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
7.00M |
| Short Ratio |
24.53 |
| Short % of Float |
38.47% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
6.82 |
| Revenue |
n/a |
| Operating Income |
-100.36M |
| Net Income |
-93.24M |
| Free Cash Flow |
-69.04M |
| Net Cash |
479.81M |
| Net Cash / Share |
9.84 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-18.32% |
| ROE |
-28.87% |
| ROIC |
-34.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
3 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
2 |
Analyst Consensus: Overweight
Price Target
$90.17*
(31.24% upside)
Low
34.0
Current: 68.71
High
131.0
Target: 90.17
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -91.42 | -45.72 | -22.25 | -17.06 |
| Net Income | -85.37 | -43.54 | -23.55 | -17.10 |
| Shares Outstanding | 45.19 | 19.83 | 1.62 | 1.31 |
| Earnings Per Share | -1.89 | -2.20 | -14.54 | -13.03 |
| Operating Cash Flow | -63.01 | -38.45 | -22.57 | -17.58 |
| Capital Expenditures | -0.77 | -6.95 | -0.26 | -0.23 |
| Free Cash Flow | -63.78 | -45.40 | -22.83 | -17.81 |
| Cash & Equivalents | 496 | 179 | 85.21 | 13.42 |
| Total Debt | - | - | - | 4.99 |
| Net Cash / Debt | 496 | 179 | 85.21 | 8.43 |
| Assets | 517 | 191 | 87.03 | 14.18 |
| Liabilities | 21.17 | 7.27 | 2.83 | 7.62 |
| Book Value | 496 | 184 | -58.77 | -36.44 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Allakos Inc. |
| Country |
United States |
| Employees |
96 |
| CEO |
Robert Alexander |
Stock Information
| Ticker Symbol |
ALLK |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ALLK |
| IPO Date |
July 19, 2018 |
Description
Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.